| 1247 |
Stents Use in STEMI (Massachusetts Registry, NewYork Registry, Small Registries, HORIZONS-AMI, DEBATER, and GENIUS-STEMI) |
Donald E. Cutlip |
May. 04. 10 |
| 1246 |
Triage and Transfer for PCI in STEMI (ASSENT-4, FINESSE, CARESS-in-AMI, TRANSFER-AMI, and Several Regional Systems of STEMI Care |
Christian M. Spaulding |
May. 04. 10 |
| 1245 |
Risk-Reduction Drugs: Statin or Others (NAPLES II Trial, ARMYDA-RECAPTURE, and Other Drug-Trial Beyond Antiplatelets or Anticoagulants in ACS ) |
Anthony H. Gershlick |
May. 04. 10 |
| 1244 |
Timing of Antiplatelet Therapy for ACS (EARLY-ACS, and ACUITY) |
Mitchell W. Krucoff |
May. 04. 10 |
| 1243 |
Timing of Angiography (Early Invasive vs. Conservative) for High-Risk ACS; (TIMACS, ISAR-COOL, and ABOARD) |
Christian M. Spaulding |
May. 04. 10 |
| 1242 |
New Thienopyridine Use in ACS and PCI (TRITON-TIMI 38 and Several Subgroup Analyses, PLATO and Several Subgroup Analyses, and CHAMPION Trials) |
David Joel Cohen |
May. 04. 10 |
| 1241 |
Parenteral Anticoagulants Use in ACS (HORIZONS-AMI, and SEPIA-ACS Trial) |
Roxana Mehran |
May. 04. 10 |
| 1240 |
Clopidogrel Use in ACS and PCI (CURRENT-OASIS 7, Genetic Resistance Studies, GRAVITAS, CLARITY-TIMI 28, and PPI & DAT for ACS; VA Registry, PRINCIPLE, TRITON-TIMI 38, COGENT, and FAMOUS) |
Matthew Price |
May. 04. 10 |
| 1239 |
Glycoprotein IIb/IIIa Inhibitors at Primary PCI in STEMI (BRAVE-3, ON-TIME2, HORIZONS-AMI, MULTISTRATEGY, and FINESSE) |
Adnan Kastrati |
May. 04. 10 |
| 1238 |
Surgeon's View of Hybrid Procedures |
Tae Jin Yun |
May. 04. 10 |
